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Background: With over 50 different disorders and a combined incidence of up to 1/3000 births, lysosomal storage
diseases (LSDs) constitute a major public health problem and place an enormous burden on affected individuals
and their families. Many factors make LSD diagnosis difficult, including phenotype and penetrance variability, shared
signs and symptoms, and problems inherent to biochemical diagnosis. Developing a powerful diagnostic tool could
mitigate the protracted diagnostic process for these families, lead to better outcomes for current and proposed
therapies, and provide the basis for more appropriate genetic counseling.
Methods: We have designed a targeted resequencing assay for the simultaneous testing of 57 lysosomal genes,
using in-solution capture as the enrichment method and two different sequencing platforms. A total of 84 patients
with high to moderate-or low suspicion index for LSD were enrolled in different centers in Spain and Portugal,
including 18 positive controls.
Results: We correctly diagnosed 18 positive blinded controls, provided genetic diagnosis to 25 potential LSD
patients, and ended with 18 diagnostic odysseys.
Conclusion: We report the assessment of a next–generation-sequencing-based approach as an accessory tool in
the diagnosis of LSDs, a group of disorders which have overlapping clinical profiles and genetic heterogeneity. We
have also identified and quantified the strengths and limitations of next generation sequencing (NGS) technology
applied to diagnosis.
Keywords: In-solution enrichment, Targeted resequencing, Lysosomal storage disorders, Diagnostic odysseysIntroduction
Lysosomal storage disorders (LSDs) are rare diseases
with a combined incidence of ~1 in 1500 to 7000 live
births [1,2]. This group of inborn errors of metabolism
encompasses >50 different diseases, each characterized
by the accumulation of specific substrates [3-6]. Generally,
newborns with LSDs appear normal at birth and symp-
toms develop progressively over the first few months of* Correspondence: amarmiesse@gmail.com
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article, unless otherwise stated.life. Late-onset juvenile and adult forms of LSDs, result-
ing from chronic substrate accumulation, also occur,
but due to their varied signs and symptoms can have a
delayed diagnosis. The recent development and avail-
ability of enzyme-replacement therapy (ERT) for several
LSDs means that diagnosis early in the clinical process
is of particular relevance [7]. Most importantly, early
genetic diagnosis can provide parents with realistic in-
formation about their child’s prognosis, enable appro-
priate genetic counseling about future pregnancies, and
prevent ‘diagnostic odysseys’ for families [8].
Because the clinical features of many LSDs overlap, es-
tablishing a diagnosis solely on the basis of clinical pres-
entation is difficult. Until recently, clinicians have hadioMed Central Ltd. This is an Open Access article distributed under the terms of
tp://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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tion has been laboratory assays based on detection of the
storage product. Although many of the clinical symptoms
of different LSDs result primarily from substrate storage
anomalies, presentation varies widely, depending on type,
quantity, location, and time of extraction of the accumu-
lated storage material, thus frequently giving rise to false
negatives in biopsy analysis. Tests for elevated levels of
secreted substrate material are routinely used to examine
the pattern of glycosaminoglycans and oligosaccharides
in patients suspected of having mucopolysaccharidoses
(MPS) or disorders that present with oligosacchariduria.
Although urine screens are very sensitive, affected individ-
uals with normal urine screens have been reported mainly
in young and adults; thus, when there is a strong index
of suspicion, normal urine screening results should still
be followed by enzyme analysis [9-11]. Enzyme activity
detected in blood spots, either individually or simultan-
eously, is useful in the diagnosis of a small number of
LSDs, but needs verification with a second type of assay;
while measurement of enzyme activity in leukocytes and
plasma serves this purpose for most LSDs, a proportion
of cases may also not be detected using this method.
Other limitations with enzyme activity tests is that they
cannot detect heterozygous carriers of a disease, and are
not suitable for potentially oligogenic LSDs (not de-
scribed so far for LSD but recognized for retinitis pig-
mentosa, deaffness or ciliopathies) [12]. All of the above
methods are laborious, time-consuming, and require
accurate clinical diagnosis to reduce the number of
enzymatic assays used for each patient. Moreover, all
these techniques are semi-quantitative and subject to
high variability, leading to false positives and negatives.
In summary, diagnosis of LSDs represents a challenge
for clinicians and can take several years. Even reaching a
diagnosis with traditional techniques, a genetic diagnosis
also has to be made in order to provide the family with
appropriate genetic counseling, itself arguably as import-
ant as the diagnosis. Genetic analysis is usually not per-
formed as the primary screening tool in the diagnosis of
LSD due to the cost and delay incurred by the sequential
genetic tests necessary to diagnose any particular disor-
ders. However, with the availability of next-generation
sequencing (NGS) technologies, a genetically based diag-
nosis can be completed in 4 or 6 weeks, while reducing the
cost to that of Sanger sequencing a single gene [13-15].
Here, we present the results of a pilot project to evaluate
the application of NGS to mutation screening in a diagnos-
tic context. We show the strengths and limitations of this
approach and, although this assay would never suffice as
the sole diagnostic tool, we propose it as a useful adjunct
to diagnosis for specialists in everyday clinical management
who might suspect an LSD, given its ability to provide
accurate information in a short time.Methods
Ethics statement
The study protocol adhered to the tenets of the Declar-
ation of Helsinki and was approved by the local Ethics
Committee (Comité Ético de Investigación Clínica de
Galicia - CEIC). Informed written consent was obtained
from each study participant. Index patients underwent a full
neurological examination in each source hospital. When-
ever available, blood samples from affected and unaffected
family members were collected for co-segregation analysis.
Probands
A total of 84 probands were collected from different
institutions in Spain and Portugal, including 18 positive
controls, and 66 patients with a suspected LSD. Positive
controls underwent biochemical test and Sanger sequen-
cing. Analyses of 13 controls and 33 patients were per-
formed with SOLiD and 5 controls and 33 patients with
Illumina platform.
LSD diagnostic suspicion index
Subjective parameter chosen by the clinical specialists
who managed each case. We asked them to choose be-
tween three degree of suspicion: high (you believe your
patient has a lysosomal disease with a high probability
due to biochemical or clinical data), low (your main sus-
picion is another condition but there is a low probability
that even if it is a lysosomal disease and it is important
to discard it), medium (in the differential diagnosis are
lysosomal diseases).
Capture array design, library construction, and NGS
A custom Sure Select oligonucleotide probe library was
designed to capture the 551 exons and exon-intron-
boundaries of 57 genes known to be associated with LSDs,
according to GeneReviews (NCBI) (Table 1) [16]. Design
includes all transcripts from each target gene. The eArray
web-based probe design tool was used for this purpose
[17]. The following parameters were chosen for probe
design: 120 bp length for baits, 5X probe-tiling frequency,
and 20 bp overlap in restricted regions identified by the
implementation of eArray’s Repeat Masker program. A
total of 5037 unique baits, covering 183,440 bp, were gen-
erated and synthesized by Agilent Technologies (Santa
Clara, CA, USA). Sequence capture, enrichment, and
elution were performed according to the manufacturer’s
instructions.
SOLiD4 platform
Briefly, 3–4 μg of each genomic DNA was fragmented
by sonication (Covaris S2, Massachusetts, USA), purified
to yield 150–180 bp fragments and end-repaired. Adaptor
oligonucleotides from Agilent technologies were ligated
on repaired DNA fragments, which were then purified,
Table 1 Genes included in the NGS-LSD assay and their
associated disorders
Gene Lysosomal storage dirorder
SMPD1 Niemann-Pick Disease, Type A and B
NPC1 Niemann-Pick Disease, Type C1
NPC2 Niemann-Pick Disease, Type C2
LIPA Wolman Disease
GLA Fabry Disease
GLB1 GM1-Gangliosidosis, Type I, II, III
GM2A GM2-Gangliosidosis, AB Variant
HEXA Tay-Sachs Disease
HEXB Sandhoff Disease
GBA Gaucher Disease
GAA Pompe Disease
IDUA MPS I: Hurler/Scheie
IDS MPS II: Hunter Syndrome
SGSH MPS IIIA: Sanfilippo Type A
NAGLU MPS IIIB: Sanfilippo Type B
HGSNAT MPS IIIC: Sanfilippo Type C
GNS MPS IIID: Sanfilippo Type D
GALNS MPS IVA: Morquio A
GLB1 MPS IVB: Morquio B
ARSB MPS VI: Maroteaux-Lamy Syndrome
GUSB MPS VII: Sly Syndrome
HYAL1 MPS IX
ASAH1 Farber Disease
ARSA Metachromatic Leukodystrophy
GALC Krabbe Disease
PSAP Prosaposin deficiency
NEU1 Mucolipidosis I: Sialidosis
FUCA1 Fucosidosis
LAMP2 Danon Disease: Glycogen Storage Disease IIB
LAMP3 Candidate Gene For LSD
GNPTAB Mucolipidosis II Alpha/Beta
GNPTG Mucolipidosis III Gamma
MCOLN1 Mucolipidosis IV: Sialolipidosis
MAN2B1 Mannosidosis, Alpha B, Lysosomal
MANBA Mannosidosis, Beta A, Lysosomal
PPT1 Ceroid Lipofuscinosis, Neuronal, 1
TPP1 Ceroid Lipofuscinosis, Neuronal, 2
CLN3 Ceroid Lipofuscinosis, Neuronal, 3 (Batten Disease)
CLN5 Ceroid Lipofuscinosis, Neuronal, 5
CLN6 Ceroid Lipofuscinosis, Neuronal, 6
CLN7 Ceroid Lipofuscinosis, Neuronal, 7
CLN8 Ceroid Lipofuscinosis, Neuronal, 8
CLN10 Ceroid Lipofuscinosis, Neuronal, 10
Table 1 Genes included in the NGS-LSD assay and their
associated disorders (Continued)
CTSA Galactosialidosis
CTNS Cystinosis
SLC17A5 Sialic Acid Storage Disease
CTSK Pyknodysostosis
NAGA Schindler Disease
SUMF1 Multiple Sulfatase Deficiency
HPS1 Hermansky-Pudlak Syndrome Type 1
AP3B1 Hermansky-Pudlak Syndrome Type 2
HPS3 Hermansky-Pudlak Syndrome Type 3
HPS4 Hermansky-Pudlak Syndrome Type 4
HPS5 Hermansky-Pudlak Syndrome Type 5
HPS6 Hermansky-Pudlak Syndrome Type 6
DTNBP1 Hermansky-Pudlak Syndrome Type 7
BLOC1S3 Hermansky-Pudlak Syndrome Type 8
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amplified by 12 PCR cycles. The libraries (500 ng) were
then hybridized to the Sure Select biotinylated-RNA
capture library for 24 h. After hybridization, washing, and
elution, the captured fraction underwent 12 cycles of PCR
amplification with barcoded primers followed by purifica-
tion and quantification by qPCR. Forty-eight barcoded
samples were then pooled in groups for sequencing on a
SOLiD4 platform as single end 50 bp reads. 12 sample
libraries were loaded per octet of SOLiD4 slide.HiSeq2000 platform
The library preparation for capturing of selected DNA
regions was performed according to the SureSelect XT
Target Enrichment System protocol for Illumina paired-
end sequencing (Agilent). In brief, 3 μg of genomic DNA
was sheared on a Covaris™ E220 focused-ultrasonicator.
Fragment size (150-200 bp) and quantity were confirmed
with an Agilent 2100 Bioanalyzer 7500 chip. The frag-
mented DNA was end-repaired, adenylated and ligated
to Agilent indexing-specific paired-end adaptors. The DNA
with adaptor-modified ends was PCR amplified (6 cycles,
Herculase II fusion DNA polymerase) with SureSelect
primers, quality controlled using the DNA 7500 assay
specific for a library size of 250–350 bp, and hybridized for
24 hr at 65°C. The hybridization mixture was washed in the
presence of magnetic beads (Dynabeads MyOne Streptavi-
din T1, Life Technologies), and the eluate PCR amplified
(16 cycles) to add index tags using SureSelectXT Indexes
for Illumina. The final library size and concentration was
determined using an Agilent 2100 Bioanalyzer 7500 chip
and sequenced on an Illumina HiSeq 2000 platform with a
paired-end run of 2 × 76 bp, following the manufacturer’s
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HiSeq 2000.
Data filtering and analysis pipeline
SOLiD4 platform
Image analysis and base calling was performed using the
SETS (SOLiD experimental Tracking Software) pipeline
to generate primary data. Sequence reads were aligned
to the reference human genome UCSC hg19 using Life
Technologies’ BioScope suite v1.3.1. Default parameters,
recommended for targeted resequencing, were used. Vari-
ant calling was performed using two software programs
in parallel: the diBayes alignment algorithm embeded in
the Bioscope suite [18] and the Genome Analysis Toolkit
(GATK) v1.5, a software package developed at the Broad
Institute (Cambridge, MA) to analyze next-generation
resequencing data [19]. The GATK Unified Genotyper
is a state-of-the-art variant caller for NGS data and used
extensively in human sequencing projects. The variant
detection pipeline uses well-established statistical models
for recalibration of the base quality score and variant
calling. Low stringency parameters were selected to avoid
false negatives although a high rate of false positives was
expected.
HiSeq2000 platform
Base calling and quality control were performed on the
Illumina Real Time Analysis (RTA) sequence analysis
pipeline. Sequence reads were trimmed to keep only those
bases with a quality index > 10 and then mapped to Human
Genome build hg19 (GRCh37), using a Genome Multitool
(GEM) [20] and allowing up to 4 mismatches. Reads not
mapped by GEM were submitted to a last round of map-
ping with BLAT-like Fast Accurate Search Tool (BFAST)
[21]. Uniquely mapping non-duplicate read pairs were
locally realigned with GATK. Samtools suite [22] was
used to call single nucleotide variants (SNVs) and short
INDELs, taking into account all reads per position. Vari-
ants on regions with low mappability or variants in which
there was not at least one sample with read depth ≥10
were filtered out.
Sanger sequencing
To verify the DNA sequence variants detected by NGS,
we amplified the target sites and flanking sequences of
each variant with specific primers designed using the
free software Primer3 v.0.4.0 [23]. Next, we sequenced
the PCR products using the Sanger method to ascertain
the precision of the variants identified by NGS. Sequen-
cing reactions consisted of 1.0 μl of previously purified
PCR products (ExoSAP-IT, USB, Cleveland, OH), 1 μl of
each primer, and 1 μl of Big Dye Terminator v3.1 from
the Cycle Sequencing kit (Applied Biosystems, Foster
City, CA). The reactions were run in an ABI 3730 DNAAnalyzer (Applied Biosystems, Foster City, CA). Analysis
was performed with the Staden package free software.
Detection of gross indels
A simple homemade Excel table was designed for detec-
tion of gross deletions and duplications encompassing
one or more exons. The table contained coverage peak
areas for each exon and patient. Ratios of successive peak
areas between different patients were compared to identify
homozygous and heterozygous gross indels. To establish
the extremes of deletion it is necessary to perform cDNA
Sanger sequencing studies.
Filtering of annotated sequence data
We received the bam files and the annotated sequencing
variants in Excel tables from the two platforms. Raw
data were filtered with custom designed scripts using the
free, open source statistical software R package [24]. We
have submitted all novel variants included in the article
to ClinVar database [25] from NCBI and to the Locus
Specific Mutation Databases (LSMDs) from Human Gen-
ome Variation Society [26].
Assessment of the pathogenicity of variants
The following criteria were applied to evaluate the
pathogenic nature of novel variations identified by NGS:
1) stopgain, frameshift and splicing variants, considered
the most likely to cause disease; 2) the presence of a sec-
ond mutant allele, taken to indicate recessive inheritance;
3) cosegregation; 4) the absence of the variant in other
samples; 5) frequency <0.01 in the 1000 g2012 database;
and 6) for missense mutations, amino acid conservation
and prediction of pathogenicity. To evaluate criterion 6),
we used the freely available bioinformatics web tools: SIFT
(Sorting Intolerant From Tolerant) [27], Polyphen-2 [28]
and Mutation Taster [29]. To evaluate the possible effect
of synonymous variant in gene splicing we used the
Human Splicer Finding web tool [30].
Results and discussion
Statistical data from two platforms
Total target sequence length, including coding exons and
exon-intron junctions from 57 LSD genes, was 183,440 bp.
Coverage distribution across the designed region was rep-
licated among the samples for each platform. The overall
sequence depth was 456X for SOLiD4 and 7,416X for
HiSeq2000. SOLiD4 yielded a total of up to 158,863,367
raw 50-mer reads with 87.28% mapped reads overall. A
total of 94.5% of bases were covered by at least 20 reads
and the mean percentage of bases not covered per sample
was 2.6%. The HiSeq2000 run resulted in (1292,371,000)
QC-passed reads with 88.47% mapped reads overall. A
total of 99.97% of bases were covered by at least 20 reads,
SANGER 
confirmation
SOLiD4 RAW DATA
Filter1: variants which fullfill these 4 conditions
1- placed in exonic or splicing regions
2- NRA frecuency ≤ 0.01 en 1000g2012 database
3- %NRA ≤ 4 in our study group
4- functional significance (indels, stopgain, splicing,  
missense)
12.179 variants
219 variants
Filter2: variants which fulfill 3 of these 4 conditions:
1- coverage≥20
2- %NRA ≥30
3- MQV≥15 for both alleles
4- (reference MQV –variant MQV) ≤5
77 variants
Figure 1 Global flowchart of the filtering pipeline used for
selection of most likely pathogenic mutations, starting from
SOLiD4 raw data. (NRA: non-reference allele).
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reads of only 0.03%.
Limitations of the enrichment method
The most important challenge for this kind of enrich-
ment is that local sequence architecture has a strong ef-
fect on the efficiency of DNA enrichment for individual
exons [31]. Exons close to repetitive regions are not fully
covered, because the eArray web tool does not design
baits in repetitive regions. In our assay 5 exons were
affected by this initial lack of baits. We tried to minimize
this pitfall by using the 5X bait-tailing option, to reduce
the gaps as much as possible. However, our results showed
that such an approach overcame this problem only if
coverage was increased maximally. Another significant
limitation of the enrichment method is that coverage
decreases dramatically, even to zero, for exons located in
CpG islands. With 456X coverage, 22 of 57 genes showed
gaps in coverage (<20X) in one exon, and 6 in more than
one exon, with the most damaged genes being IDUA,
GBA, and GAA. Thus, our NGS-LSD assay did not detect
mutations in the IDUA gene in a patient with biochem-
ically confirmed Hurler disease. With 7416X coverage no
gaps were found in any of LSD genes. Therefore, to estab-
lish this assay as a diagnostic screening tool for routine
use it will be essential to eliminate sequence gaps. Because
enrichment failures with hybrid capture were reprodu-
cible, they may be amenable to rescue by individual PCRs
or probe redesign.
Filtering of raw data
The main challenge of using NGS for diagnostic applica-
tions will be in interpreting the massive number of gen-
omic variants detected by sequencing platforms. Fast and
reliable identification of causative variants will be crucial to
the implementation of this technology in diagnostics. In
our study, simple filters based on variant function and
frequency, and careful selection of index cases versus
controls, was found to be a useful way of discriminating
between pathogenic mutations and background polymor-
phisms. Priority was given to variants considered to be spe-
cific to individual patients, based on the assumption that a
mutation underlying such a monogenic disorder is highly
penetrant and rare. It was also assumed that these muta-
tions are likely to be coding and to have a major pheno-
typic effect.
From the 12,179 and 52,303 variants detected by the
SOLiD4 and HiSeq platforms, respectively, successive
filters were applied to reduce these numbers to 77 and
68. SOLiD4 raw data provided by Bioscope SNP calling
software were filtered twice, using specifically designed
R scripts (Figure 1). Filter 1 selected variants with the
following specific features: 1) non-reference allele (NRA)
frequency ≤0.01 in the 1000 g2012 database; 2) locationin exonic or splicing regions; 3) non-synonymous, indels,
stopgain, or splicing; and 4) NRA frequency ≤4% in our
study group. This filter reduced the initial number of
variants to 219. Filter 2 then discriminated between real
and false-positive changes, by fulfilling at least 3 of follow-
ing conditions: 1) coverage of position ≥20; 2) percentage
of NRA reads ≥30; 3) mean quality values (MQV) of ref-
erence and variant ≥15; 4) [reference-variant] MQV ≤5.
The number of variants was reduced to 77, implying a
false-positive rate of 65%. Careful observation of the
false-positive variants showed that they appeared in charac-
teristic areas which either had a low coverage or a sudden
drop in coverage, or were considered coverage ‘valleys’.
Therefore such false positives were the result of coverage
irregularities arising from local sequence architecture, and
were largely avoidable, either by improving enrichment
efficiency or increased coverage, as shown by the results
obtained with the Illumina NGS-LSD assay. Filter 2 was
also adjusted by checking variants by Sanger sequencing
(see next section) and comparing data from two different
variant-calling software packages, Lifescope and GATK.
Variants obtained from HiSeq2000 passed through the
same Filter 1 as in SOLiD4, reducing the number of
EXON 5 GLB1 gene
EXON 7+8
CONTROL
FATHER of P3 
CLN3 gene
A
B
CONTROL
P20
Figure 2 Heterozygous macrodeletions detected by LSD-NGS.
A) GLB1 exon 5 deletion; B) CLN3 exon 7 + 8 deletion. The area of
the coverage peak for each deleted exon is half that seen in the
corresponding control sample.
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necessary as the high coverage achieved meant that the
false-positive rate was insignificant using HiSeq2000.
Assessment of the novel genetic tool for LSD diagnosis
All putatively pathogenic variants detected by either of
the two platforms were subsequently tested by Sanger
sequencing of both the index case and parents, and all
were confirmed. A more thorough analysis of the variants
detected by SOLiD4 was carried out, to test the reliability
of Filter 2 in discrimination of real from false variants. Of
the 71 missense variants which passed Filter 2 and were
confirmed with Sanger sequencing (see previous section),
83% were found to be real and 17% false-positive. Of 48
variants which did not pass through Filter 2, 14 were
additionally selected for having values near the limit for
one or more conditions; all of these were then verified
as false-positive. Therefore, while overall we had a false-
positive rate of 17%, we conclude that the second filter
detected real variants with a high degree of confidence.
If, on the other hand, we had only allowed variants fulfill-
ing all 4 conditions of Filter 2 to pass through, we would
not have had any false positives but instead we would have
had a rate of 9% of false negatives. A comparison of the
two variant calling software packages was also found to be
useful in discriminating between real and false variants, as
none of the false positives seen using Lifescope appeared
when using GATK and vice versa.
Detection of gross deletions
One advantage of NGS-based strategies, as opposed to
Sanger sequencing, is that, in addition to SNVs and small
indels, they can also detect gross deletions and insertions
which affect one or more exons. Thus, we detected two
heterozygous macrodeletions, one an exon 5 deletion in
GLB1 (P20), and another an exon 7 + 8 deletion in CLN3
(C18) (Figure 2). We also detected the same CLN3 macro-
deletion in a homozygous state (C2 and P3; not shown).
Limitations of SNP calling software
Using Bioscope software, heterozygous variants were found
with a percentage of NRA reads between 30 and 50%,
while homozygous variants had percentages of between 70
and 100%. Lower percentages were seen for small deletions
and insertions, comprising a potential problem with this
technology. On the other hand, a comparison of the two
SNP calling software packages showed there to be a signifi-
cant proportion of false negatives with each package. Thus,
of 105 variants confirmed by Sanger sequencing, Bioscope
had failed to detect 3 (2.8%) and GATK failed to detect 9
(8.5%). This illustrates the importance of using more than
one type of variant calling software in parallel, to discrim-
inate between real and false variants as well as to reduce
the false-negative rate as much as possible.Diagnosis achieved with the NGS-LSD screening tool
We applied the NGS-LSD method to 84 probands with
a spectrum of early-onset neurodegenerative disorders
that were potentially caused by a deficiency in one of the
57 LSD proteins (Figure 3). From these 84, we selected
18 control samples with mutations previously identified
by Sanger sequencing, three of which had only a single
mutation in the affected gene (C14, 15, 18). Of the 33
mutations expected, all but one was detected using the
NGS-LSD assay (Table 2). The undetected mutant was
located on exon 1 of the NAGLU gene (C8), which was
not covered by hybridization baits, due to its being lo-
cated close to repetitive regions. It is important to high-
light that this mutation would have been detected with
Illumina platform. For the 66 unclassified patients, an
LSD suspicion index was assigned, as low, moderate, or
high in each case. For each case, clinical data and tests
carried out for diagnostic purposes, including genetic,
were collected (Table 3). Based on the presence of one
or two mutations, we were able to achieve genetic diag-
nosis in 26 patients. Twenty-two of these were found to
carry two mutations in the same gene, consistent with
clinical and/or biochemical features and establishing a
genetic diagnosis (Table 4). A further 26 patients were
found to be carriers of mutations (Tables 4 and 5). In all
cases, the gene harboring a mutation was carefully ex-
amined to find any other variant that might have been
initially undetected due to its location in an intronic re-
gion, synonymity, or being a gross indel. Thus, a second
mutation was found in 4 patients (P11, 20, 21, 23). Of
84 probands
66 genetic unclassified patients18 genetic
classified patients
17 
2x
1 
1x
21
2x
26 (1x)
17 21
19 (0x)
4 
2x
18
1x
19
0x
4 21 2
4
1x
18 19
No diagnosedDiagnosed patients ??
+
+ + + + ? -
- --
seek for biochemical / clinical correlation
seek for a second mutation (IGV)
Figure 3 Diagnosis achieved using NGS-LSD. (1x: one mutation found; 2x: two mutations found in the same gene; VCS: variant calling
software; ??: not confirmed.)
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to confirm or exclude disease, in four patients (P12, 27,
28, 29) chosen for the severity of the variant found and
correlation between genotype and phenotype. Biochemical
tests on P27, P28 and P29 gave negative results. In P12
the diagnosis of NPC2 could not be confirmed but it could
not be discarded neither (filipin staining was unconclusive
but this is not unusual in a percentage of NPC2 patients
and only one heterozygous pathogenic mutation was
found). It is important to emphasize that in the current
study we were readily able to confirm biochemically muta-
tion pathogenicity in the majority of genes analyzed, but
this is not possible for pathologies that have no biochem-
ical markers and in which confirmation will need to be
obtained by other methods. No mutations were found in
19 probands (p49-p65), but the LSD index of suspicion
was low for all but one of these.
Unexpected diagnoses
In cases P7, P9 and P11, the diagnoses were unexpected,
adding significant value to our method. In case P7, the
patient’s history did not initially suggest type 1 gangliosi-
dosis (GM1), due to presence of cerebellar atrophy on
magnetic resonance imaging (MRI) at first consultation
(age 2 years) and a consistently raised lactic acid level in
both blood and cerebrospinal fluid (CSF). Together with
updated clinical data, therefore, a mitochondrial cytopa-
thy seemed likely and a muscle biopsy was performed,
which showed a slight deficiency in complex I of the
mitochondrial respiratory chain. Subsequent electroneur-
ography (at 4.7 years) showed results consistent with amixed polyneuropathy. This finding, along with the clin-
ical data, MRI, and minimal deficiency in complex I, sug-
gests a probable neuroaxonal dystrophy. With enzymatic
and genetic data from the NGS-LSD assay, we concluded
that this child suffered from a late infantile GM1 that
could be categorized as atypical due to the presence
of cerebellar atrophy, mixed polyneuropathy, and in-
creased lactate in the blood and CSF. In classical GM1,
MRI is usually normal or shows some late brain atrophy,
while polyneuropathy and high lactate levels are not
usually present.
Case P9 was shown to have juvenile type 2 gangliosidosis
(GM2), following a delayed suspicion of a storage disorder
due to the late onset and low specificity of symptoms, and
slow progression of the disease. In case P11, ceroid lipo-
fuscinosis neuronal (CLN) was initially suspected due to
epilepsy, cognitive regression, and a loss of memory and
expressive language. Progressive multifocal epilepsy was
refractory to combination therapy, the patient’s vision
worsened, and he appeared ataxic and lost bowel control.
There was also a reduced retinal vascular tree with papil-
lary pallor, thought to signify the onset of retinopathy;
however the detection of a severe mutation in the GM2-
associated gene HEXA altered the diagnosis. P11 currently
has progressive optic atrophy. Whilst infantile GM2 is
easy to recognize due to a cherry-red spot in the fundus,
juvenile GM2 is difficult without the identification of
genetic variants, as discussed above. As it is shown in the
Table 4, second mutation in HEXA for P11 was synonym-
ous. Familial co segregation was demonstrated and the
program Human splicing finder predicted the disruption
Table 2 Results obtained for positive controls included in NGS-LSD assay
CC GENE REF_SEC NT CHANGE AA CHANGE ZIG MD DIAGNOSIS OMIM
C1 ARSA NM_000487 c.1046delC p.P349fs HO + Metachromatic leukodystrophy 250100
C2 CLN3 NM_000086 c.461-280_677 + 382del966 p.[Gly154Alafs*29, Val155_Gly264del] HO + Ceroid lipofuscinosis, neuronal, 3 204200
C3 FUCA1 NM_000147 c.464C > T p.S155F HT - Fucosidosis 230000
FUCA1 NM_000147 c.790C > T p.R264X HT -
C4 GALNS NM_000512 c.281G > T p.R94L HO + Mucopolysaccharidosis type IVA 253000
C5 GLB1 NM_000404 c.1581G > A p.W527X HO + GM1 gangliosidosis 230500
C6 GNPTAB NM_024312 c.1208 T > C p.I403T HT + Mucolipidosis III alpha/beta 252600
GNPTAB NM_024312 c.1999G > T p.E667X HT +
C7 GUSB NM_000181 c.526C > T p.L176F HT + Mucopolysaccharidosis VII 253220
GUSB NM_000181 c.530C > T p.T177I HT -
C8 NAGLU NM_000263 c.900C > T p.R234C HT + Sanfilippo B 252920
C9 NEU1 NM_000434 c.700G > A p.D234N HT + Sialidosis 256550
NEU1 NM_000434 c.1021C > T p.R341X HT +
C10 SGSH NM_000199 c.120C > G p.Y40X HO + Sanfilippo A 252900
C11 SMPD1 NM_000543 c.739G > A p.G247S HO + Niemann-Pick disease, type A 257200
C12 TPP1 NM_000391 c. 622C > T p.R208X HO + Ceroid lipofuscinosis, neuronal, 1 256730
C13 CTSA NM_000308 c.448G > A p.V150M HT - Galactosialidosis 256540
CTSA NM_000308 c.284delC p.P95Lfs HT -
C14 NPC1 NM_000271 c.1552C > T p.R518W HT + Niemann-Pick disease, type C 257220
C15 NPC1 NM_000271 c.2594C > T p.S865L HT + Niemann-Pick disease, type C 257220
C16 SLC17A5 NM_012434 c.918 T > G p.Y306X HT + Sialic acid storage disorder,infantile 269920
SLC17A5 NM_012434 c.500 T > C p.L167P HT -
C17 ARSB NM_000046 c.427delG p.V143Sfs HO + Mucopolysaccharidosis VI 253200
C18 CLN3 NM_000086 c.461-280_677 + 382del966 p.[Gly154Alafs*29, Val155_Gly264del] HT + Ceroid lipofuscinosis, neuronal, 3 204200
CC: Control Code (C1-C12 processed with SOLiD4 platform; C13-C18 processed with HiSeq2000); REF SEQ: reference sequence for which mutations are annotated; NT and AA CHANGE: nucleotide and amino acid
change; ZIG: zigosity; HO: homozygotes; HT: heterozygotes; MD: Mutation description in Human Gene Mutation Database (+: previously associated with pathology; −: not previously associated).
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Table 3 Diagnostic suspicions and biochemical/histopathological tests for patients diagnosed using the NGS-LSD tool
PC AO AD GD NGS-LSD Initial signs Diagnostic suspicions Biochemical-histopathology studies* Other genetic studies*
P1 2Y - 12Y CLN5 Clumsiness, frequent falls, apraxic gait CLN VL; SBIOP + . PPT1, TTP1
P2 4Y - 7Y CLN6 Clumsiness, myoclonic movements GM2, GCL, MLD, Fabry, Schindler,
MANSA, MANBA, MPS, CLN
EA: HEXA, HEXB, GLA, NAGA, MANBA,
MAN2B1, MPS, GALC, ARSA, PPT1, TTP1
MFSD8
P3 3Y - 16Y CLN3 Language regression, school inattention,
social isolation
CDG, GM1, GM2, GSL, Schindler,
GSD II, III, CLN
VL; FC; SPA ; EA: GLB1, HEXB, CTSA,
NAGA, GAA, AGL; SBIOP + .
P4 2Y - 23Y CLN7 Language delay, clumsiness CLN SBIOP +; EA: CLN2. CLN1
P5 4Y - 16Y CLN3 Conduct disorder, attention deficit disorder CLN VL +; SBIOP, MBIOP, NBIOP + . PPT1, TTP1, CLN3, CLN5, CLN8
P6 3Y 4Y 7Y MLD Leukodystrophy Spastic paraparesia EA: ARSA +
P7 1Y - 9Y GM1 Global developmental delay, gait instability CDG; RCCD; INAD MBI; NBIOP +; MBS; SPA; EA: HEXA, HEXB
P8 2Y 7Y 4Y GM2 Language delay, conduct disorder Unspecific global developmental delay,
Neurodegenerative disease; CLN, GM2
SBIOP; MBS; EA: HEXA + . Caryotype; Fragile X; Smith-Magenis
P9 2Y - 14Y GM2 Clumsiness, frequent falls Ataxia, Attention deficit disorder MBI Caryotype; Fragile X; CGH-60 k array.
P10 3Y 9Y 12Y GM1 Clumsiness, frequent falls, language delay RS, MPSIII, GM1 MBS, U-GAGs; EA: GLB1+ Caryotype, Fragile-X, MECP2
P11 5Y - 22Y GM2 Learning problems, language difficulties CLN SBIOP CLN3, CLN8
P12 13Y - 18Y NPC2# Clumsiness, short stature MTDPS; RCCD; SCA; DRPLA MBIOP; RCCFS; EA: muscular Coenzima Q10 mtADN(muscle); MTATP6; tRNALeu
(UUR); SCA1,2,3,6,7,12,17; ATN1
P13 18 M - 4Y ML II,III Growth delay, macrocephaly MPS U-GAGs SHOX
P14 12 M 3Y 3Y GM2 Psycomotor regression, language regression RS, GM2 EA: HEXA +, HEXB MECP2
P15 0 M 3 M 1Y GM1 Hypotonia, hepatomegaly, cardiomyopathy,
bony abnormalities
GSD II EA: GAA
P16 9 M 2Y 2Y MPSVI Bilateral costal deformity, macrocephaly AA, MPS U-GAGs, Dermatan sulfate in urine, EA: ARSB
P17 0 M - 2Y ML II,III Hypotonia, microcephaly, jaundice MPS MBS, U-OLG, U-GAGs Caryotype; CGH array
P18 2 M 3Y 6Y MPSII Bilateral inguinal hernia MPS U-GAGs; EA: IDS +
P19 1Y 4Y 5Y MPSI Clubfoot, arthrogryposis, clawed hands MPS U-GAGs; EA: IDUA +, IDS, ARSB
P20 0 M 1Y 1Y GM1 Hypotonia, severe psycomotor delay GM1, GM2, GSL, ML I MBS; VL; U-GAGs; EA: GBL1 +, HEXA,
HEXB, CTSA, NEU1
P21 18 M 3Y 3Y GM2 Unsteady gait, frequent falls TORCH, Leukodystrophy EA:
P22 2Y - 6Y CLN8 Cognitive regression, epilepsy Lennox syndrome, CLN PBIOP +
P23 3Y - 9Y CLN10 Psycomotor regression, dystonia, epilepsy Neuroaxonal dystrophy, sphingolipidosis MBIO mtDNA
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Table 3 Diagnostic suspicions and biochemical/histopathological tests for patients diagnosed using the NGS-LSD tool (Continued)
P24 3Y 5Y 23Y MPSIIIB Language delay, conduct disorder,
learning disabilities, hypoacusia
MPS Heparan sulfate +
P25 1Y - 6Y GM2AB Developmental delay, regression GM2, GSD II EA: HEXA, HEXB, GAA (+); HPS GM2 + GAA
P26 4Y - 25Y† CLN8 Cognitive regression, epilepsy CLN CLN6
Abbreviations: PC Patient Code, AO Age of Onset (Y: years; M: months; †deceased), AD Age at Diagnosis, GD age at Genetic Diagnosis, NGS-LSD diagnosis reached with our NGS tool, CLN Neuronal Ceroid Lipofuscinosis,
MLD metachromatic leukodystrophy, GM1 and 2 Gangliosidosis I and II, NPC2 Niemann-Pick disease, type C2, ML II III mucolipidosis III alpha/beta, MPS mucopolysaccharidosis, GM2AB Gangliosidosis type II, AB variant,
MANSA Mannosidosis, alpha-, types I and II, MANBA mannosidosis beta, CDG congenital disorder of glycosylation, GSL galactosialidosis, GSD glycogen storage disease, GSD II Pompe disease, RCCD respiratory chain
complex deficiency, INAD infantile neuroaxonal dystrophy, RS Rett syndrome, AA autoimmune arthritis, ML I sialidosis, TORCH Band-like calcification with simplified gyration and polymicrogyria, MBS metabolic study,
SPA sialotransferrin profile analysis, VL vacuolated lymphocytes in peripheral blood, FC foam cells in bone marrow, RCCFS respiratory chain complex functional studies, GCL globoid cell leukodystrophy or Krabbe
disease, SCA spinocerebellar ataxia, EA enzymatic assay, U-GAGs urinary glycosaminoglycan levels, U-OLG urinary oligosaccharides levels, SBIOP skin biopsy, MBIOP muscle biopsy, NBIOP nerve biopsy, HPS pathological
study, mtDNA mithocondrial DNA deletions, depletion and punctual mutations, MTDPS mitochondrial depletion syndrome, CGH comparative genomic hybridization; #: not confirmed; *All results were
negative unless indicated by a plus sign.
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Table 4 Diagnosis achieved using the NGS-LSD tool
PC AO GDD IS GENE OMIM REF SEC NT CHANGE AA CH MT SS PP CS ZIG MD BA DIAGNOS
P1 2Y 10Y Mod CLN5 608102 NM_006493 c.335G > C/c.835G > A p.R112P/p.D279N 099/0.99 0/0.16 1/1 + H + NA Finnish variant late infantile CLN
P2 4Y 4Y Mod CLN6 606725 NM_017882 c.794_796del p.S265del - - - H + NA Early juvenile late infantile CLN
P3 3Y 12Y High CLN3 607042 NM_000086 c.461-280_677 +
382del966
p.[Gly154Alafs*29,
Val155_Gly264del]
- - - H + NA Juvenile CLN
P4 2Y 21Y Mod MFSD8 611124 NM_152778 c.881C > A p. T294K 0.99 0 0.99 + H + NA Turkish variant late infantile CLN
P5 4Y 12Y High CLN3 607042 NM_000086 c.371_372insT p.Y124fs - - - H - NA Juvenile CLN
P6 3Y 4.5Y High ARSA 607574 NM_000487 c.465 + 1G > A ———————— - - - + H + + Metachromatic leukodystrophy
P7 1Y 8Y Low GLB1 611458 NM_000404 c.922 T > C p.F308L 0.99 0 1 + H - + GM1 gangliosidosis
P8 3Y 1Y High HEXA 606869 NM_000520 c.533G > A p.R178H 0.99 0 1 + H + + GM2 gangliosidosis, B1variant
P9 4Y 10Y Low HEXA 606869 NM_000520 c.1496G > A p.R499H 0.99 0 1 H + + GM2 gangliosidosis, juvenil (TS)
HEXA NM_000520 c.1003A > T p.I335F 0.99 0 0.97 H +
P10 3Y 7Y High GLB1 611458 NM_000404 c.602G > A p.R201H 0.99 0.02 1 H + + GM1 gangliosidosis
GLB1 NM_000404 c.1188_1188dupG p.P397fs - - - H -
P11 5Y 18Y High HEXA 606869 NM_000520 c.155C > A p.S52X - - - + H + + GM2 gangliosidosis juvenile (TS)
HEXA NM_000520 c.1305C > T p.Y435Y - - - H -
P12 13Y 6Y Low NPC2 NM_006432 c.441 + 1G > A ————————— - - - H - - Niemann-Pick disease, type C2?
P13 18 M 3Y High GNPTAB 607840 NM_024312 c.2354 T > G p.L785W 0.71 0.09 0.022 + H - + Mucolipidosis II/III
GNPTAB NM_024312 c.1774G > A p.A592T 0.98 0.01 0.955 H -
P14 12 M 4Y High HEXA 606869 NM_000520 c.718_719insT p.K240fs H - + GM2 gangliosidosis (TS)
HEXA NM_000520 c.1003A > T p.I335F 0.99 0.00 0.467 H +
P15 0 M 1Y High GLB1 611458 NM_000404 c.671_672delAT p.H224Qfs + H - +* GM1 gangliosidosis
P16 9 M 1Y High ARSB 611542 NM_000046 c.382_384delCTC p.L128del H - +* Mucopolysaccharidosis VI
P17 0 M 3Y High GNPTAB 607840 NM_024312 c.3739_3742delCTTT p.E1248fs + H - + Mucolipidosis II/III
P18 2 M 6Y High IDS 300823 NM_000202 c.425C > T p.S142F 0.98 0.00 0.998 + H + +* Hunter Syndrome
P19 3Y 5Y High IDUA 252800 NM_000203 c.1205G > A p.W402X + H + +* Hurler Syndrome
IDUA NM_000203 c.1874A > G p.Y625C 0.98 0.00 0.99 H -
P20 10 M 2Y High GLB1 611458 NM_000404 c.947A > G p.Y316C 0.999 0 0.79 H + +* GM1 gangliosidosis
GLB1 NM_000404 c.458-401_552 +
1033del1529
————————— H +
P21 20 M 4Y High HEXA 606869 NM_000520 c.459 + 5G > A ————————— H + +* GM2 gangliosidosis (TS)
HEXA NM_000520 c.533G > A p.R178H 0.99 0 1 H +
P22 2Y 4Y High CLN8 607837 NM_018941 c.509C > G p.T170R 0.999 0.00 0.999 + H + NA Ceroid lipofuscinosis, neuronal, 8
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Table 4 Diagnosis achieved using the NGS-LSD tool (Continued)
P23 3Y 9Y High CTSD 116840 NM_001909 c.470C > T p.S157L 0.98 0.03 0.005 + HT - NA Ceroid lipofuscinosis, neuronal, 10
CTSD NM_001909 c.353-12G > A ————————— - - - HT - pendɛ
P24 3Y 23Y High HGSNAT 610453 NM_152419 c.1250 + 1G > A ————————— - - - HT + +* Sanfilippo C
HGSNAT NM_152419 c.1270G > A p. G424S 0.999 0.59 1 HT +
P25 1Y 6Y High GM2A 613109 NM_000405 c.333delC p. C112Vfs - - - HO - +# GM2 gangliosidosis, AB variant
P26 4Y >20Y High CLN8 607837 NM_018941 c.792C > G p. N264K 0.97 0 0.99 + HO - NA Ceroid lipofuscinosis, neuronal, 8
Notes and abbreviations: Samples from Patients P1-P12 were processed using SOLiD4 (Life Technologies), but those from P13-P26 using HiSeq2000 (Illumina); PC: Patient Code; AO: Age of Onset (Y: years; M: months);
GDD: Genetic Diagnosis Delay (Y: years; M: months: DEC: deceased); IS: index of suspicion of LSD (Mod: moderate); REF SEC: reference sequence for which mutations are annotated; Nt and Aa Change: nucleotide and
amino acid change (population frequency ≤0.01 according to 1000G2012 database); MT: Mutation Taster, SS: Sift Score and PP: Polyphen 2 score (in silico values to assess pathogenicity of missense variants); CS: Cose-
gregation; ZIG: zigosity; HO: homozygote; HT: heterozygote; HE: hemizygous; MD: Mutation description in Human Gene Mutation Database (+: previously associated with pathology; −: not previously associated); BA:
Biochemical assay (+: positive; NA: test not available; −: negative); CLN: Neuronal Ceroid Lipofuscinosis; TS: Tay-Sachs; *Levels detected before NGS-LSD assay; ɛmRNA splicing analysis; #histopathology congruent with
GM2 diagnosis.
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Table 5 Results found for patients remaining un-diagnosed
PC IS Gene Ref sec Coding variants* dbSNP ID MAF Zig MD BA
P27 High MANBA NM_005908 c.1922G > A p.R641H – HT + NegΨ
P28 High HYAL1 NM_033159 c.676C > T p.R226C – HT - NCI
HEXB NM_000521 c.383 T > G p.L128R – HT - NegΨ
P29 High SMPD1 NM_000543 c.1460C > T p.A487V – HT + NegΨ
P30 Low NEU1 NM_000434 c.1070G > A p.R357Q – HT - NCI
P31 Mod MFSD8 NM_152778 c.50C > G p.T17R – HT - NCI
P32 Low NAGA NM_000262 c.697G > A p.V233M – HT - NCI
NPC1 NM_000271 c.665A > G p.N222S rs1805081 0.001 HT + NCI
P33 Low SMPD1 NM_000543 c.1550A > T p.E517V – HT + NCI
P34 High SGSH NM_000199 c.308A > G p.K103R – HT - NCI
CLN6 NM_017882 c.755G > C p.R252P – HT - NCI
P35 Low TPP1 NM_000391 c.1117C > G p.Q373E – HT - NCI
GAA NM_000152 c.1367G > T p.R456M – HT - NCI
P36 High CLN5 NM_006493 c.606G > A p.M202I – HT - NCI
P37 High SMPD1 NM_000543 c.8G > A p.R3H – HT - NCI
P38 Low IDUA NM_000203 c.251G > C p.G84A – HT - NCI
P39 Low IDS NM_000202 c.754G > A p.D252N – HO + Neg*
P40 Low CLN3 NM_000086 c.995C > T p.A332V – HT - NA
P41 High CLN5 NM_006493 c.726C > A p.N242K – HT - NA
P42 High IDUA NM_000203 c.650G > A p.R217Q – HT - NCI
NPC1 NM_000271 c.2257G > A p.V753M – HT - NCI
P43 Mod ASAH1 NM_177924 c.2 T > C p.M1T – HT - NCI
P44 Low SMPD1 NM_000543 c.1460C > T p.A487V – HT + NCI
P45 Low CLN3 NM_000086 c.995C > T p.A332V – HT - NA
P46 Low CLN5 NM_006493 c.606G > A p.M202I – HT - NA
GALNS NM_000512 c.1127G > A p.R376Q – HT + NCI
P47 Low GNPTG NM_032520 c.857C > T p.T286M – HT + NCI
NPC1 NM_000271 c.3535A > G p.M1179V rs61731969 0.002 HT - NCI
P48 Low MAN2B1 NM_000528 c.844C > T p.P282S rs45576136 0.003 HT - NCI
Notes and abbreviations: Samples from P27-39 were processed using SOLiD4; those from P40-P48 using HiSeq2000; P49-P66 no mutation was found. PC: Patient Code;
IS: Index of LSD Suspicion (Mod: moderate); *detected with frequency ≤0.01 in 1000 g2012 database; MAF: minor allele frequency; Zig: zygosity; HO: homozygote; HT:
heterozygote; MD: Mutation description in Human Gene Mutation Database (+: previously associated with pathology; −: not previously associated); BA: Biochemical
assay (+: positive; NA: test not available; Neg: negative; NCI: not clinically indicated; Ψ Enzimatic assay; *GAGs).
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eous creation of a new silencer motif.
A finding of interest was the presence of a hemizygous
variant of the Hunter-associated gene IDS in patient P25.
While this mutation is already registered in Human Gene
Mutation Database (HGMD) as associated with the Hunter
phenotype, the patient showed none of the clinical features
usually found in Hunter patients; he did not showed in-
creased levels of urine GAGs and no skeletal deformities
were shown in radiological test, excluding completely a
Hunter diagnosis. This lends further weight to what has
long been suspected, that we have only seen the ‘tip of the
iceberg’ of genotype-phenotype associations in clinical gen-
etics and that NGS will change some universally acceptedparadigms and lead to new genetic prescripts, such as the
implication of more than one gene in classically monogenic
disorders [32].
Time-to-diagnosis and cost: comparisons with
Sanger sequencing
The period between onset of disease and genetic diagnosis
(GDD column, Table 4) also enhances the value of the
NGS-LSD tool. Diagnostic delay in our study was on aver-
age 7 (range 1–23) years. Using NGS-LSD ended 14–15
diagnostic odysseys, thus opening the way for genetic coun-
seling and carrier tests. In terms of cost, the difference
between classical and next-generation sequencing tech-
nology is $2400 and $0.1 per million bases, respectively.
Fernández-Marmiesse et al. Orphanet Journal of Rare Diseases 2014, 9:59 Page 14 of 16
http://www.ojrd.com/content/9/1/59Two examples from the current study serve to illustrate
the difference between two technologies. Although a CLN
was strongly suspected, patient P5 (with 13 years of diag-
nostic delay) underwent five classical genetic analyses with-
out a positive result and at a total cost of about 4000€.
With an early NGS-LSD assay, the diagnosis could have
been made in 8 weeks at a cost of about 900€. In case P3
several diseases were suspected over a period of 12 years,
including GM1, Sandhoff, galactosialidosis, Schindler dis-
ease and CLN. If the NGS-LSD tool had been used on first
suspicion, the time-to-diagnosis would have been reduced
to 1–2 months, and the cost to that of a single genetic
analysis.
Future approaches to reduce non-diagnosis
The current study ended with 39–40 patients still un-
diagnosed, although 64% of these had a low or moderate
index of suspicion of LSD. Clearly, these undiagnosed
cases indicate a significant problem with our proposed
tool, which is due to the considerable phenotypic overlap
between many LSD and non-LSD neurodevelopmental
conditions for which the genetic variants are not included
in the NGS-LSD technique. To address this problem, we
are currently developing a broad-range genetic panel that
encompasses most known neurometabolic disorders, the
NGS-NMD1 tool, which will be updated as new genes
come to light with continued research. Such an approach
will form an important next step in optimizing the
neurometabolic diagnostic process. Six of our undiag-
nosed patients are currently undergoing whole-exome
resequencing.
Application of NGS-LSD to clinical diagnosis
NGS technologies have significantly improved sequen-
cing capacity in the past 5 years. These technologies are
now widely used for research purposes and are starting
to find their way into clinical applications [33-35]. Whole-
genome and exome sequencing approaches are being
successfully implemented in research projects [31,36-42],
but are not yet routine strategies in diagnosis due to high
costs, long turnover times (run and analysis time) and
ethical issues. Targeted resequencing, on the other hand,
is appealing in a clinical setting due to lower sequencing
costs, shorter sequencing time, simpler data analysis, and
greater sensitivity per gene due to the greater coverage
achieved [43,44]. The results of the current study also
illustrate the importance of good coverage to reliability
in detection of mutations in NGS in clinical settings.
Due to the nature of the technology, NGS also brings
with it uncertainties and limitations of a higher order of
magnitude than previously seen in genetic diagnosis. How-
ever, uncertainty in genetic testing is nothing new, and we
also have the foresight and fortitude to develop tools to deal
with these issues. Assays must also be carefully validatedwith pilot projects to assess sensibility and accuracy of
these new technologies. Several groups are working in this
direction, designing resequencing assays for a panel of
genes related to groups of diseases that have similar
clinical manifestations and difficult diagnoses [45-54].
To the best of our knowledge, the current study is the
first to use NGS in LSD screening. Overall, it shows that
a high rate of detection of mutations is possible when
sequence coverage is sufficient and gaps due to limita-
tions in the enrichment method can be overcome. Our
results show that the combination of in-solution based
capture and NGS can be used for the parallel screening
of multiple disease genes and can successfully identify
disease-causing mutations. This assay, therefore, can be
used as a support genetic tool, that always in combin-
ation with biochemical and clinical data could facilitate a
diagnosis. Finally, we have shown the power of our ap-
proach as a tool for making diagnoses that are particularly
challenging and for bringing diagnostic odysseys to a more
rapid conclusion. It will be important, therefore, to con-
tinue to work with specialists to optimize this powerful
and promising technology for the benefit of patients and
their families”.
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